Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241926 | 0.87 | HTR1A (0.40) | HTR1AADRA1DADRA1AADRA1BCYP1A2 | |
| SCHEMBL4986900 | 0.84 | HTR1A (0.49) | HTR1AADRA1DADRA1AADRA1BCYP1A2 | |
| SCHEMBL243582 | 0.83 | FERMT2 (0.61) | HTR1AADRA1DADRA1AADRA1BCCR1 | |
| SCHEMBL13993581 | 0.83 | PDE5A (0.44) | HTR1AADRA1DADRA1AADRA1BCYP1A2 | |
| SCHEMBL241983 | 0.83 | FERMT2 (0.51) | HTR1AADRA1DADRA1AADRA1BCYP1A2 | |
| SCHEMBL241245 | 0.82 | CYP3A4 (0.41) | HTR1AADRA1DADRA1AADRA1BCYP1A2 | |
| SCHEMBL241000 | 0.81 | KDM4E (0.61) | HTR1AADRA1DADRA1AADRA1BCYP1A2 | |
| SCHEMBL242703 | 0.81 | HRH3 (0.60) | MEN1LMNAPOLBKMT2AMITF | |
| SCHEMBL242051 | 0.79 | MEN1 (0.55) | MEN1LMNAPOLBKMT2AMITF | |
| SCHEMBL238033 | 0.78 | HTR1A (0.41) | HTR1AADRA1DADRA1AADRA1BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012015875-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015901-A1 | METHODS FOR TREATING GASTRIC AND PANCREATIC MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120004235-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2286812-A1 | Solubilized topoisomerase poisons | Rutgers, The State University (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7781587-B2 | antitumor; breast cancer; 8,9-Dimethoxy-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2010088544-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-2196205-A1 | Topoisomerase poisons | Rutgers, The State University (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1465625-B1 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7517883-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7049315-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060052381-A1 | Solubilized topoisomerase poisons | LAVOIE EDMOND J | 2006-03-09 | — | — | US | disclosed |
| EP-1465625-A4 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050009824-A1 | Solubilized topoisomerase poisons | RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE | 2005-01-13 | — | — | US | disclosed |
| EP-1465625-A2 | SOLUBILIZED TOPOISOMERASE POISONS | Rutgers, The State University (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003041660-A2 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009824-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | HTR1A 2063/4885ADRA1D 3047/4885ADRA1A 2094/4885 |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | HTR1A 2063/4885ADRA1D 3047/4885ADRA1A 2094/4885 |
| US-20120004235-A1 | METHODS TO TREAT CANCER | TP53, CCNY, ABCB1 | HTR1A 2786/4885ADRA1D 1895/4885ADRA1A 566/4885 |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | HTR1A 2063/4885ADRA1D 3047/4885ADRA1A 2094/4885 |
| US-20060052381-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | HTR1A 2063/4885ADRA1D 3047/4885ADRA1A 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.